Patents by Inventor Xiaoqing Qiu
Xiaoqing Qiu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11926544Abstract: The invention discloses a biological desulfurizer for removing organic sulfur in fracturing flowback fluid and application thereof. The biological desulfurizer includes a compound with a triazine structure formed by modifying chitosan with aldehydes and inorganic salts. The triazine structure has a good removal effect on hydrogen sulfide and organic sulfur such as mercaptan and sulfide. The biological desulfurizer of the invention has a sulfur capacity of up to 250 g/kg and a desulfurization efficiency of over 95% in 15 min. It can effectively remove the stink of sulfur-containing working water, improve the working environment of the well site, and reduce the impact of sulfur compounds on the atmospheric environment during the development of oil and gas fields.Type: GrantFiled: October 16, 2023Date of Patent: March 12, 2024Assignees: CHINA PETROLEUM & CHEMICAL CORPORATION, CHINA PETROLEUM & CHEMICAL CO., LTD. OF NORTH BRANCHInventors: Xiaoqing Qiu, Xiang Wang, Guisheng Wang, Guofeng Li, Jiawei Zhang, Lei Song, Xia Wang, Qianli Xu, Puyan Hou
-
Patent number: 10962354Abstract: The invention relates to a selection method of loss control materials for lost circulation control in fractured reservoirs based on photoelastic experiments. By using the photoelastic material to simulate rigid lost circulation material, obtaining photoelastic images and load curves during a loading process of plugging zones formed by the lost circulation material, selecting the lost circulation material according to structure stability of plugging zones.Type: GrantFiled: December 10, 2020Date of Patent: March 30, 2021Assignee: Southwest Petroleum UniversityInventors: Chengyuan Xu, Xiaopeng Yan, Yili Kang, Hao Zhang, Haoran Jing, Jingyi Zhang, Chong Lin, Lijun You, Xiaoqing Qiu
-
Patent number: 10071358Abstract: Provided are a novel antibiotic preparation method and platform system based on the method, belonging to a novel drug development method. The method is based on a fixed structural formula: F—R, wherein F is an effect area, and R is an identification area. At the prior art level, the present invention can quickly develop a specific novel antibiotic for most pathogenic microorganisms or biological cells. Also provided is a platform for implementing the method, ensuring that the novel antibiotic is developed in an efficient streamlined process.Type: GrantFiled: December 10, 2012Date of Patent: September 11, 2018Assignee: PROTEIN DESIGN LAB, LTD.Inventor: Xiaoqing Qiu
-
Patent number: 9765378Abstract: The invention provides a method of preparing a new recombinant antibacterial polypeptide medicine, which primarily relates to liquid culture medium formula suitable for large-scale production of the antibacterial polypeptide, as well as optimization of the enlarged culture parameters.Type: GrantFiled: March 1, 2012Date of Patent: September 19, 2017Assignee: Creative Trio Biotech (Beijing) Co., Ltd.Inventors: Xiaoqing Qiu, Rongqi Li, Xiangli Zhang, Xiaofeng Zhang
-
Patent number: 9611299Abstract: Provided are methods for highly expressing recombinant protein of engineering bacteria and the use thereof. The method comprises the following steps: (1) engineering bacteria of Escherichia coli with pET system are transfected with recombinant mutated plasmid to obtain positive monoclonal colonies; (2) the positive monoclonal colonies are enriched to obtain a seed bacteria solution, and the seed bacteria solution is induced to enrichment and growth in a large amount; and (3) the bacteria supernatant containing the recombinant protein as the expression target is separated, and then the recombinant protein in the bacteria supernatant is extracted and purified. The method is characterized in that the engineering bacteria of Escherichia coli with pET system are E. coli B834 (DE3).Type: GrantFiled: November 23, 2012Date of Patent: April 4, 2017Assignee: Protein Design Lab, Ltd.Inventor: Xiaoqing Qiu
-
Patent number: 9572347Abstract: An agent for virus inactivation capable of exhibiting inactivation action based on structural destruction such as degradation and decomposition against viruses, which comprises a monovalent copper compound such as cuprous oxide, cuprous sulfide, cuprous iodide, and cuprous chloride as an active ingredient, and a virus inactivation material, which contains the agent for virus inactivation on a surface of a substrate and/or inside of the substrate.Type: GrantFiled: December 22, 2010Date of Patent: February 21, 2017Assignees: THE UNIVERSITY OF TOKYO, KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGYInventors: Kazuhito Hashimoto, Kayano Sunada, Masahiro Miyauchi, Xiaoqing Qiu, Yoshinobu Kubota, Hitoshi Ishiguro, Ryuichi Nakano, Jitsuo Kajioka, Yanyan Yao
-
Publication number: 20160304927Abstract: The invention provides a method of preparing a new recombinant antibacterial polypeptide medicine, which primarily relates to liquid culture medium formula suitable for large-scale production of the antibacterial polypeptide, as well as optimization of the enlarged culture parameters.Type: ApplicationFiled: March 1, 2012Publication date: October 20, 2016Applicant: BEIJING CREATED TRIBIOTECHNOLOGY CO., LTD.Inventors: Xiaoqing QIU, Rongqi LI, Xiangli ZHANG, Xiaofeng ZHANG
-
Patent number: 9359429Abstract: Provided are a hybridoma cell CGMCC No. 4783 that secretes a monoclonal antibody of an anti-cyanobacteria cell surface antigen, and the secreted monoclonal antibody thereof. Also provided are an anti-cyanobacteria recombinant antibody polypeptide, encoding gene, preparation method and use thereof. The anti-cyanobacteria recombinant antibody polypeptide is composed of an anti-cyanobacteria antibody mimetic polypeptide operably linearly connecting to the carboxyl terminal of an Escherichia coli polypeptide. The anti-cyanobacteria antibody mimetic polypeptide is a polypeptide with cyanobacteria identifying and binding capability designed based on an antigen binding fragment of the monoclonal antibody secreted by the CGMCC No. 4783 hybridoma cell. The anti-cyanobacteria recombinant antibody polypeptide directly form an ion channel on the cell membrane of a cyanobacteria to kill the cyanobacteria, targeted killing the cyanobacteria (prokaryote) without killing other beneficial eukaryotic cell algae.Type: GrantFiled: March 27, 2012Date of Patent: June 7, 2016Assignee: Protein Design Lab, Ltd.Inventor: Xiaoqing Qiu
-
Patent number: 9248432Abstract: A copper compound-carried titanium oxide photocatalyst which is excellent in a photocatalytic activity and a viral inactivation property and a production process for the same can be provided by a copper compound-carried titanium oxide photocatalyst comprising titanium oxide in which a content of rutile type titanium oxide is 50% by mole or more and a monovalent copper compound and a divalent copper compound which are carried on a surface of the titanium oxide described above and a production process for a copper compound-carried titanium oxide photocatalyst, comprising a step of carrying a monovalent copper compound and a divalent copper compound on a surface of titanium oxide in which a content of rutile type titanium oxide is 50% by mole or more.Type: GrantFiled: June 22, 2012Date of Patent: February 2, 2016Assignees: THE UNIVERSITY OF TOKYO, SHOW A DENKO K.K.Inventors: Kazuhito Hashimoto, Masahiro Miyauchi, Xiaoqing Qiu, Kayano Sunada, Yasushi Kuroda, Yasuhiro Hosogi, Ding Li, Yoshiki Shimodaira
-
Patent number: 9073989Abstract: The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic comprising an antibody mimetic antibody, its preparation methods and uses thereof. A novel antibiotic comprising a antibody mimetic covalently bonded to the carboxyl end of a colicin polypeptide or a channel-forming domain polypeptide of a colicin, wherein said colicin is selected from the group consisting of Colicin E1, Ia, Ib, A, B, N; wherein said antibody mimetic being yielded by fusing two complementarity determining regions (CDRs), VHCDR1 and VLCDR3 through a cognate framework region (VHFR2) of an immunoglobulin; wherein said the immunoglobulin specifically recognizes the bacterial porins. Its antibacterial ability is a thousandfold powerful than normal antibiotics. Due to its unique action mechanism, drug resistance resulted in mutation can hardly be acquired by pathogenic bacteria. And the antibiotic will not hurt normal human cells when it kills pathogenic bacteria.Type: GrantFiled: January 25, 2011Date of Patent: July 7, 2015Assignee: PROTEIN DESIGN LAB, LTDInventor: Xiaoqing Qiu
-
Publication number: 20140349880Abstract: Provided are a novel antibiotic preparation method and platform system based on the method, belonging to a novel drug development method. The method is based on a fixed structural formula: F—R, wherein F is an effect area, and R is an identification area. At the prior art level, the present invention can quickly develop a specific novel antibiotic for most pathogenic microorganisms or biological cells. Also provided is a platform for implementing the method, ensuring that the novel antibiotic is developed in an efficient streamlined process.Type: ApplicationFiled: December 10, 2012Publication date: November 27, 2014Applicant: PROTEIN DESIGN LAB, LTD.Inventor: Xiaoqing Qiu
-
Patent number: 8883161Abstract: The present invention provides a fusion polypeptide against EB virus-induced tumor, which comprises an antibody or a mimetic antibody against EB virus and an ion channel forming colicin selected form E1, Ia, Ib, A, B, N and their mutants. The present invention also provides a colicin Ia mutant, which comprises mutations of G11A, H22G, A26G, V31L, and H40D. The present invention also provides a gene, vector, preparation method and use of the fusion polypeptide, and provides a gene and use of the mutant.Type: GrantFiled: February 26, 2010Date of Patent: November 11, 2014Assignee: Protein Design Lab, Ltd.Inventor: Xiaoqing Qiu
-
Publication number: 20140322754Abstract: Provided are methods for highly expressing recombinant protein of engineering bacteria and the use thereof. The method comprises the following steps: (1) engineering bacteria of Escherichia coli with pET system are transfected with recombinant mutated plasmid to obtain positive monoclonal colonies; (2) the positive monoclonal colonies are enriched to obtain a seed bacteria solution, and the seed bacteria solution is induced to enrichment and growth in a large amount; and (3) the bacteria supernatant containing the recombinant protein as the expression target is separated, and then the recombinant protein in the bacteria supernatant is extracted and purified. The method is characterized in that the engineering bacteria of Escherichia coli with pET system are E. coli B834 (DE3).Type: ApplicationFiled: November 23, 2012Publication date: October 30, 2014Inventor: Xiaoqing Qiu
-
Publication number: 20140170170Abstract: Provided are a hybridoma cell CGMCC No. 4783 that secretes a monoclonal antibody of an anti-cyanobacteria cell surface antigen, and the secreted monoclonal antibody thereof. Also provided are an anti-cyanobacteria recombinant antibody poly-peptide, encoding gene, preparation method and use thereof. The anti-cyanobacteria recombinant antibody polypeptide is composed of an anti-cyanobacteria antibody mimetic polypeptide operably linearly connecting to the carboxyl terminal of an Escherichia coli polypeptide. The anti-cyanobacteria antibody mimetic polypeptide is a polypeptide with cyanobacteria identifying and binding cap-ability designed based on an antigen binding fragment of the monoclonal antibody secreted by the CGMCC No.4783 hybridoma cell. The anti-cyanobacteria recombinant antibody polypeptide directly form an ion channel on the cell membrane of a cyanobacteria to kill the cyanobacteria, targeted killing the cyanobacteria (prokaryote) without killing other beneficial eukaryotic cell algae.Type: ApplicationFiled: March 27, 2012Publication date: June 19, 2014Applicant: Protein Design Lab,LtdInventor: Xiaoqing Qiu
-
Publication number: 20130344124Abstract: An agent for virus inactivation capable of exhibiting inactivation action based on structural destruction such as degradation and decomposition against viruses, which comprises a monovalent copper compound such as cuprous oxide, cuprous sulfide, cuprous iodide, and cuprous chloride as an active ingredient, and a virus inactivation material, which contains the agent for virus inactivation on a surface of a substrate and/or inside of the substrate.Type: ApplicationFiled: December 22, 2010Publication date: December 26, 2013Applicants: KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY, THE UNIVERSITY OF TOKYOInventors: Kazuhito Hashimoto, Kayano Sunada, Masahiro Miyauchi, Xiaoqing Qiu, Yoshinobu Kubota, Hitoshi Ishiguro, Ryuichi Nakano, Jitsuo Kajioka, Yanyan Yao
-
Publication number: 20130281283Abstract: A copper compound-carried titanium oxide photocatalyst which is excellent in a photocatalytic activity and a viral inactivation property and a production process for the same can be provided by a copper compound-carried titanium oxide photocatalyst comprising titanium oxide in which a content of rutile type titanium oxide is 50% by mole or more and a monovalent copper compound and a divalent copper compound which are carried on a surface of the titanium oxide described above and a production process for a copper compound-carried titanium oxide photocatalyst, comprising a step of carrying a monovalent copper compound and a divalent copper compound on a surface of titanium oxide in which a content of rutile type titanium oxide is 50% by mole or more.Type: ApplicationFiled: June 22, 2012Publication date: October 24, 2013Applicants: THE UNIVERSTIY OF TOKYO, SHOWA DENKO K.K.Inventors: Kazuhito Hashimoto, Masahiro Miyauchi, Xiaoqing Qiu, Kayano Sunada, Yasushi Kuroda, Yasuhiro Hosogi, Ding Li, Yoshiki Shimodaira
-
Patent number: 8563503Abstract: The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic, its nucleotide sequence, methods of construction and uses thereof. A novel antibiotic, wherein the end of any peptide of the allosteric colicin is connected linearly to the end of peptide of the Staphylococcus aureus pheromone AgrD I, AgrD II, AgrD III, AgrD IV or Staphylococcus epidermidis pheromone. Wherein the allosteric colicin being yielded by artificially mutating the amino acid residues G11A, H22R, A26G, V31L and H40K in the peptide chain of wild type Colicin E1, Ia, Ib, A, B, N, or their ion channel-forming structural domain. In comparison with the traditional antibiotics, the novel antibiotics in the present invention are not likely to lead to drug resistance and cause hypersensitivity reaction.Type: GrantFiled: February 7, 2011Date of Patent: October 22, 2013Assignee: Protein Design Lab. Ltd.Inventor: Xiaoqing Qiu
-
Publication number: 20130066051Abstract: The present invention provides a fusion polypeptide against EB virus-induced tumor, which comprises an antibody or a mimetic antibody against EB virus and an ion channel forming colicin selected form E1, Ia, Ib, A, B, N and their mutants. The present invention also provides a colicin Ia mutant, which comprises mutations of G11A, H22G, A26G, V31L, and H40D. The present invention also provides a gene, vector, preparation method and use of the fusion polypeptide, and provides a gene and use of the mutant.Type: ApplicationFiled: February 26, 2010Publication date: March 14, 2013Applicant: PROTEIN DESIGN LAB, LTD.Inventor: Xiaoqing Qiu
-
Publication number: 20120202734Abstract: The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic, its nucleotide sequence, methods of construction and uses thereof. A novel antibiotic, wherein the end of any peptide of the allosteric colicin is connected linearly to the end of peptide of the Staphylococcus aureus pheromone AgrD I, AgrD II, AgrD III, AgrD IV or Staphylococcus epidermidis pheromone. Wherein the allosteric colicin being yielded by artificially mutating the amino acid residues G11A, H22R, A26G, V31L and H40K in the peptide chain of wild type Colicin E1, Ia, Ib, A, B, N, or their ion channel-forming structural domain. In comparison with the traditional antibiotics, the novel antibiotics in the present invention are not likely to lead to drug resistance and cause hypersensitivity reaction.Type: ApplicationFiled: February 7, 2011Publication date: August 9, 2012Applicant: PROTEIN DESIGN LAB, LTD.Inventor: Xiaoqing Qiu
-
Publication number: 20120190826Abstract: The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic comprising an antibody mimetic antibody, its preparation methods and uses thereof. A novel antibiotic comprising a antibody mimetic covalently bonded to the carboxyl end of a colicin polypeptide or a channel-forming domain polypeptide of a colicin, wherein said colicin is selected from the group consisting of Colicin E1, Ia, Ib, A, B, N; wherein said antibody mimetic being yielded by fusing two complementarity determining regions (CDRs), VHCDR1 and VLCDR3 through a cognate framework region (VHFR2) of an immunoglobulin; wherein said the immunoglobulin specifically recognizes the bacterial porins. Its antibacterial ability is a thousandfold powerful than normal antibiotics. Due to its unique action mechanism, drug resistance resulted in mutation can hardly be acquired by pathogenic bacteria. And the antibiotic will not hurt normal human cells when it kills pathogenic bacteria.Type: ApplicationFiled: January 25, 2011Publication date: July 26, 2012Applicant: Protein Design Lab, Ltd.Inventor: Xiaoqing Qiu